Navigation Links
Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
Date:5/24/2012

PITTSBURGH, POTTERS BAR, England and MILAN, May 24, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its UK and Italy-based subsidiaries have launched Ibandronic Acid Film Coated Tablets POM, 150 mg. This product is the generic version of Roche's Bonviva® Tablets, a treatment for osteoporosis(1).

Mylan CEO Heather Bresch said: "This launch represents another day-one generic for Mylan's businesses in the UK and Italy. We are excited to be adding generic Ibandronic Acid to our strong portfolio of more than 350 products in the UK and 340 products in Italy, as we continue to deliver on our commitment of providing high quality and affordable medicines to patients around the world."

Ibandronic Acid Film Coated Tablets POM had sales of approximately 8.5 million euros (7.5 million pounds Sterling) in the UK and sales of approximately 27 million euros in Italy for the 12 months ending March 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the wo
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MISSISSAUGA, ON , May 29, 2015 /CNW/ ... COV), an advanced medical technologies company, is delighted ... quarter ended March 31, 2015, which includes revenue ... for the quarter of $264,340. Revenue from advanced wound ... ended March 31, 2015 increased 24% to $1,742,672 ...
(Date:5/29/2015)... 29, 2015  Epic Sciences announced today that the ... metastatic castrate resistant prostate cancer patients, at the ... Clinical Oncology. This application expands the investigational utility ... platform to characterize circulating tumor cell (CTC) ... patients have heterogeneous clonal CTC populations harboring separate ...
(Date:5/29/2015)... May 29, 2015  World-renowned prostate surgeon and New York ... the benefit of MR/Ultrasound Fusion-Guided Biopsy for detecting ... Prostate Cancer Center at Lenox Hill Hospital is the ... in New York City . We,ve seen ... prostate cancers. The use of an MRI makes for a ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... enzyme that stitches all-important,molecular adjustments onto proteins contorts ... Sept. 18 St. Jude Children,s,Research Hospital investigators ... array of proteins would instantly be reduced to ... for proteins to,"accessorize" in order to regulate their ...
... Analysis Shows HUMIRA Effectively Treats Adult Patients with ... Duration of Disease, ... PARIS, Sept. 18 More psoriasis patients,achieve ... compared to patients who interrupt their therapy, according ...
Cached Medicine Technology:St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins 2St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins 3Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 2Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 3Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 4Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 5Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 6Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 7Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment 8
(Date:5/30/2015)... 2015 The iconic American actor, and ... hosting a new segment on Medical Malpractice. This segment ... malpractice in the health care field. , According to ... medical malpractice suits were filed, roughly only 20% of ... out of court, while the remaining 30% were tossed ...
(Date:5/30/2015)... “ Milli the Snail ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... engages and educates children. , Interactive mobile games for children ... content and games they are playing are doing much for ...
(Date:5/30/2015)... Nevada (PRWEB) May 30, 2015 Venus ... of acne scars, large pores, deep wrinkles, stretch marks, ... licensed medical professional, such as Dr. F. Victor Rueckl ... of the clinical trials in Las Vegas. This body ... technology into a system that delivers proven results through ...
(Date:5/29/2015)... CA (PRWEB) May 29, 2015 Displays and ... that has lowered the price of hanging signs ; ... Hanging signs that hang down from ceiling rigging points at ... over the trade show floor. These signs are very ... there are additional costs for installation and dismantle labor and ...
(Date:5/29/2015)... May 29, 2015 Based in St. Louis, ... awareness shirts for a couple of months now and ... latest release, which reads “I’m not misbehaving, I have Autism, ... the parent’s of an autistic child in order to start ... , Not only are they raising awareness through the autism ...
Breaking Medicine News(10 mins):Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:La La Land Shirts Is Busy Spreading Autism Awareness with Complimentary Shipping on Their New Shirt 2
... uninsured accounted for almost 1 out of 5 ... -- An estimated 50 million, or 42 percent, of ... hospital emergency departments were billed to the Medicaid and ... Thursday. , Uninsured patients accounted for nearly 18 percent ...
... , , ABA program will ... CALDWELL, N.J., July 31 Caldwell College will launch the ... (ABA), a well developed scientific discipline that is best known for ... Caldwell,s program was recently approved by the New Jersey Commission ...
... July 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases,Inc. (HTDS:PK), ... MEVAC-DTaP (Diphtheria, Tetanus and Acellular,Pertussis Combined Vaccine, adsorbed) had ... The sample analysis is expected to be completed,within the ... Terry Yuan CEO of HTDS said (sic) "We welcome ...
... 31 As the world prepares for a probable ... Pittsburgh researchers are controlling the spread of infectious diseases ... (NIH) grant to establish a Center of Excellence in ... the NIH,s Modeling of Infectious Disease Agent Study (MIDAS) ...
... July 31, 2009 Raytheon Company (NYSE: RTN ... public health-led team of first responders and hospital personnel in ... information. , , The EPTS, ... of victims during mass casualty incidents by providing selected patient ...
... expect meds to relieve stress, personal troubles, researchers caution, ... growing number of Americans now have a positive opinion ... About five out of six people surveyed felt psychiatric ... also expected the medications could help people deal with ...
Cached Medicine News:Health News:ER Visits Mostly by Medicare, Medicaid Recipients 2Health News:Caldwell College Receives Approval to Launch First Ph.D. for Applied Behavior Analysis-Autism Treatment in New Jersey 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 2Health News:Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier 3Health News:Pitt receives $13.4 million NIH grant to create virtual models for epidemics 2Health News:Raytheon to Provide California First Responders and Healthcare Personnel Electronic Patient Tracking System 2Health News:Psych Drugs Gaining Widespread Acceptance 2Health News:Psych Drugs Gaining Widespread Acceptance 3
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
... an elastic belt to help lift the weight ... Apron features "all around protection to cover you ... wearing and removing a breeze. For additional back ... - they reduce pressure on the vertebrae and ...
Unshielded...
... II EEG system is a fully digital 32-channel ... any practice or hospital need. It can be ... a laptop computer for out-of-lab data collection, or ... custom designed carts that will hold a high ...
Medicine Products: